CME Information

In support of improving patient care, The Robert Larner College of Medicine at The University of Vermont is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Insert correct credit wording here/listing credits approved (you will be provided with this information once approved).

**Meeting Disclaimer:** Regarding written materials and information received, written or otherwise, during this Conference, the scientific views, statements, and recommendations expressed during this activity represent those of the authors and speakers and do not necessarily represent the views of the University of Vermont.

**Relevant Financial Relationships\***

All those with control of content (speakers, planners, moderators, reviewers, staff) who have relevant financial relationships with “ineligible companies” are listed below. (*An “ineligible company” is defined as those whose primary business is producing, marketing, selling, reselling or distributing healthcare products used by or on patients.*)

# No Interests to Disclose: Financial Interests to Disclose

# Relationships have been Mitigated\*:

* John Doe, MD
* John Smith, RN
* Jane Doe, PharmD
* Jane Smith, MD – Speaker’s Bureau for Glaxo
* Joe Doe, PharmD – Major Stockholder for Pfizer

***\*Note: UVM CMIE staff who reviewed this activity had no financial interests to disclose.***

**Support received from Ineligible Companies:**

* We have not received any support for this activity.

**OR**

* Grants from – list ineligible companies:
* In-Kind Equipment from – list ineligible companies:

\*Having a financial relationship with an ineligible company, or discussing an unlabeled use of an ineligible product, may not prevent a speaker from making a presentation. However, the existence of the relationship must be made known to the planning committee prior to the conference, so that any relevant financial interest may be mitigated prior to the talk.

Rev. 5/5/21